PL2709991T3 - Zastosowanie antagonistów CXCR4 w leczeniu zespołu WHIM, mielokateksji, neutropenii i limfocytopenii - Google Patents

Zastosowanie antagonistów CXCR4 w leczeniu zespołu WHIM, mielokateksji, neutropenii i limfocytopenii

Info

Publication number
PL2709991T3
PL2709991T3 PL12786739T PL12786739T PL2709991T3 PL 2709991 T3 PL2709991 T3 PL 2709991T3 PL 12786739 T PL12786739 T PL 12786739T PL 12786739 T PL12786739 T PL 12786739T PL 2709991 T3 PL2709991 T3 PL 2709991T3
Authority
PL
Poland
Prior art keywords
myelokathexis
lymphocytopenia
neutropenia
cxcr4 antagonists
whim syndrome
Prior art date
Application number
PL12786739T
Other languages
English (en)
Inventor
David C. Dale
Gary J. Bridger
Frank J. Hsu
Original Assignee
Genzyme Corporation
University Of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation, University Of Washington filed Critical Genzyme Corporation
Publication of PL2709991T3 publication Critical patent/PL2709991T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D255/00Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL12786739T 2011-05-16 2012-05-15 Zastosowanie antagonistów CXCR4 w leczeniu zespołu WHIM, mielokateksji, neutropenii i limfocytopenii PL2709991T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161486632P 2011-05-16 2011-05-16
EP12786739.8A EP2709991B1 (en) 2011-05-16 2012-05-15 Use of cxcr4 antagonists for treating WHIM syndrome, myelokathexis, neutropenia and lymphocytopenia
PCT/US2012/037970 WO2012158707A1 (en) 2011-05-16 2012-05-15 Use of cxcr4 antagonists

Publications (1)

Publication Number Publication Date
PL2709991T3 true PL2709991T3 (pl) 2021-04-06

Family

ID=81755014

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12786739T PL2709991T3 (pl) 2011-05-16 2012-05-15 Zastosowanie antagonistów CXCR4 w leczeniu zespołu WHIM, mielokateksji, neutropenii i limfocytopenii

Country Status (11)

Country Link
US (2) US20150030561A1 (pl)
EP (1) EP2709991B1 (pl)
JP (1) JP2014513727A (pl)
KR (3) KR20200016407A (pl)
CN (1) CN103596935A (pl)
BR (1) BR112013029482A2 (pl)
ES (1) ES2831049T3 (pl)
MX (1) MX365242B (pl)
PL (1) PL2709991T3 (pl)
RU (1) RU2638802C2 (pl)
WO (1) WO2012158707A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101212988A (zh) 2005-05-02 2008-07-02 建新公司 神经代谢疾病的基因治疗
US9419667B2 (en) 2013-04-16 2016-08-16 Skyworks Solutions, Inc. Apparatus and methods related to conformal coating implemented with surface mount devices
US9375406B2 (en) * 2014-09-30 2016-06-28 Taigen Biotechnology Co., Ltd. Substituted pyrimidines for mobilizing cells expressing a type 4 CXC chemokine receptor
ES2907489T3 (es) 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Métodos para el tratamiento del cáncer
CN109069486A (zh) 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
DK3393468T3 (da) * 2015-12-22 2022-12-19 X4 Pharmaceuticals Inc Fremgangsmåder til behandling af en immundefektsygdom
GB201604213D0 (en) * 2016-03-11 2016-04-27 Proximagen Ltd Drug combination and its use in therapy
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN109641838A (zh) * 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
CN116554168A (zh) 2016-06-21 2023-08-08 X4 制药有限公司 Cxcr4抑制剂及其用途
CA3027495A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
SG11201901718VA (en) * 2016-09-08 2019-03-28 Centro De Investigaciones Energeticas Medioambientales Y Tecnologicas Gene therapy for patients with fanconi anemia
CN109988153B (zh) * 2017-12-29 2021-11-19 深圳夏浠湾医药科技有限公司 一种川芎嗪衍生物及其制备方法和应用
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN113662937B (zh) * 2021-10-09 2022-08-23 江苏省人民医院(南京医科大学第一附属医院) Plerixafor在上调EFTUD2表达和抑制HBV药物中的用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (pl) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
US6001826A (en) 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9105489D0 (en) 1991-03-15 1991-05-01 Johnson Matthey Plc Improvements in chemical compounds
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
US5612478A (en) 1995-03-30 1997-03-18 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) 1995-05-02 1997-02-25 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
WO2000009152A1 (en) 1998-08-14 2000-02-24 The University Of British Columbia Therapeutic chemokine receptor antagonists
DE69914463T2 (de) 1998-03-13 2004-11-11 The University Of British Columbia, Vancouver Therapeutische chemokine rezeptor antagonisten
WO1999050461A1 (en) 1998-03-30 1999-10-07 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
CA2389545C (en) 1999-12-17 2010-08-31 Anormed Inc. Chemokine receptor binding heterocyclic compounds
CA2335109A1 (en) 2000-04-12 2001-10-12 Chemokine Therapeutics Corporation Cxcr4 agonist treatment of hematopoietic cells
US20070160574A1 (en) 2000-04-12 2007-07-12 Ahmed Merzouk Design of CXC chemokine analogs for the treatment of human diseases
ATE265219T1 (de) 2000-05-09 2004-05-15 Univ British Columbia Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
WO2001094420A1 (en) 2000-06-05 2001-12-13 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
US6489472B2 (en) 2000-09-29 2002-12-03 Anormed, Inc. Process for preparation of N-1 protected N ring nitrogen containing cyclic polyamines and products thereof
EP1389460A1 (en) 2001-05-24 2004-02-18 Kureha Chemical Industry Co., Ltd. Cxcr4-antagonistic drugs comprising nitrogen-containing compound
NZ530169A (en) 2001-07-31 2007-04-27 Anormed Inc Methods to mobilize progenitor/stem cells
US20030221931A1 (en) 2002-02-28 2003-12-04 Steve Marsh Sliding device
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
WO2004020462A1 (ja) 2002-08-27 2004-03-11 Fujii, Nobutaka Cxcr4拮抗薬およびその用途
ATE453386T1 (de) 2003-04-02 2010-01-15 Taigen Biotechnology Co Ltd Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
US7504422B2 (en) 2003-04-02 2009-03-17 Taigen Biotechnology Co. Ltd. Polyamine compounds
BRPI0514343A (pt) 2004-08-13 2008-06-10 Anormed Inc combinações de quimiocinas para mobilizar células progenitoras/tronco
US7501526B2 (en) 2005-01-20 2009-03-10 Taigen Biotechnology Synthesis of polyamine compounds
WO2006095542A1 (ja) 2005-03-04 2006-09-14 Kureha Corporation アミン系化合物を含む医薬組成物
WO2007022385A2 (en) * 2005-08-18 2007-02-22 Novartis Ag Use of cxcr4 binding molecules for the treatment of whim syndrome
US20070043012A1 (en) 2005-08-19 2007-02-22 Bridger Gary J Methods to enhance chemotherapy
US20090221683A1 (en) * 2005-10-18 2009-09-03 Caritas St.Elizabeth Medical Center Of Boston, Inc Combination of CXCR4 Antagonist and Morphogen to Increase Angiogenesis
WO2007106063A2 (en) 2006-02-24 2007-09-20 Genzyme Corporation Methods for increasing blood flow and/or promoting tissue regeneration
EP2041067A4 (en) 2006-07-11 2009-11-25 Univ Emory ANTAGONISTS OF CXCR4 COMPRISING DIAZINE AND TRIAZINE STRUCTURES FOR THE TREATMENT OF MEDICAL DISORDERS
MX2009001272A (es) 2006-08-02 2009-02-11 Genzyme Corp Terapia de combinacion.
AR062271A1 (es) 2006-08-07 2008-10-29 Genzyme Corp Uso de una cantidad efectiva de al menos un inhibidor de cxcr4, al menos un agonista de cxcr2 y g-csf para movilizar las celulas progenitoras y/o celulas madre
EA017583B1 (ru) 2007-02-28 2013-01-30 Полифор Лтд. Закрепленные на матрице пептидомиметики
EP2291963B1 (en) 2008-06-23 2016-04-27 BlackBerry Limited Method for delivering device and server capabilities
US20110245265A1 (en) 2008-08-29 2011-10-06 Genzyme Corporation Cxcr4 antagonists for kidney injury
JP2012516353A (ja) * 2009-01-30 2012-07-19 ジェンザイム・コーポレーション 血液系悪性腫瘍を治療するための方法及び組成物

Also Published As

Publication number Publication date
WO2012158707A1 (en) 2012-11-22
EP2709991B1 (en) 2020-09-02
EP2709991A1 (en) 2014-03-26
US20210161859A1 (en) 2021-06-03
KR20140045411A (ko) 2014-04-16
RU2638802C2 (ru) 2017-12-15
KR20210094672A (ko) 2021-07-29
EP2709991A4 (en) 2014-10-01
ES2831049T3 (es) 2021-06-07
JP2014513727A (ja) 2014-06-05
CN103596935A (zh) 2014-02-19
US20150030561A1 (en) 2015-01-29
BR112013029482A2 (pt) 2016-08-09
MX365242B (es) 2019-05-28
RU2013155601A (ru) 2015-06-27
KR20200016407A (ko) 2020-02-14
MX2013013308A (es) 2014-02-27

Similar Documents

Publication Publication Date Title
PL2709991T3 (pl) Zastosowanie antagonistów CXCR4 w leczeniu zespołu WHIM, mielokateksji, neutropenii i limfocytopenii
IL267066B (en) Activin-actrii antagonists and their use for the treatment of bone and other disorders
HK1246674A1 (zh) 犬尿氨酸-3-單加氧酶抑制劑、藥物組合物及其使用方法
HRP20151103T1 (en) Substituted triazolopyridines and their use as ttk inhibitors
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
HK1206264A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
HK1198619A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
HK1202415A1 (en) Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15- hetre and methods of use thereof dgla15-ohepa/ 15-hetre
IL228433A0 (en) Pyridopyrazine history and their use
EP2648697A4 (en) METHODS OF FORMING MINIEMULSIONS AND ASSOCIATED USE FOR ADMINISTRATION OF BIOACTIVE AGENTS
EP2729184A4 (en) NEW AGONISTS AND ANTAGONISTS OF THE UROTENSINERGIAN SYSTEM
PT2709991T (pt) Uso de antagonistas de cxcr4 para tratar síndrome de whim, mielocatexia, neutropenia e linfocitopenia